C. John Blankley

1.2k citations

33 papers · 1.0k indexed · h-index 17

Organic Chemistry top 5%
Computational Theory and Mathematics top 5%
- Computational Drug Discovery Methods 4
Molecular Biology
- Receptor Mechanisms and Signaling 4
- Steroid Chemistry and Biochemistry 4
- Peroxisome Proliferator-Activated Receptors 3
Pharmacology
- Pharmacogenetics and Drug Metabolism 3
Cardiology and Cardiovascular Medicine
Surgery
- Lipoproteins and Cardiovascular Health 11
- Cholesterol and Lipid Metabolism 6
Cancer Research
- Cancer, Lipids, and Metabolism 3

Co-authors: Herbert O. House Alexander Chucholowski Bruce D. Roth Robert W. Fleming M. L. HOEFLE S. KLUTCHKO John C. Hodges Drago R. Sliskovic
Cited by: Organic Chemistry Computational Theory and Mathematics Molecular Biology
Journals: Journal of Medicinal Chemistry (15 papers)The Journal of Organic Chemistry (3 papers)Journal of Pharmaceutical Sciences (1 paper)
Partner nations: United States United Kingdom Russia

In The Last Decade

C. John Blankley

32 papers receiving 921 citations

Peers

Countries citing papers authored by C. John Blankley

Since Specialization

Citations

This map shows the geographic impact of C. John Blankley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. John Blankley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. John Blankley more than expected).

Fields of papers citing papers by C. John Blankley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. John Blankley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. John Blankley. The network helps show where C. John Blankley may publish in the future.

Co-authorship network

The 25 scholars most cited alongside C. John Blankley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with C. John Blankley Line = papers co-authored together C. John Blankley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Prediction of blood-brain partitioning using Monte Carlo simulations of molecules in water Journal of Computer-Aided Molecular Design ·Yiannis N. Kaznessis,Mark E. Snow,C. John Blankley	2001	42
2	Measuring Molecular Diversity: Evaluation of Alternative Subsets Selected from Reagent Building Block Libraries for Combinatorial Chemistry Pharmacy and Pharmacology Communications ·C. John Blankley	1998	1
3	A topliss tree analysis of the HIV-protease inhibitory activity of 6-phenyl-4-hydroxy-pyran-2-ones Bioorganic & Medicinal Chemistry Letters ·Bruce A. Steinbaugh,Harriet W. Hamilton,J. V. N. Vara Prasad,Kimberly S. Para,Peter J. Tummino,Donna Ferguson,Elizabeth A. Lunney,C. John Blankley	1996	11
4	Bioisosterism in drug design: Identification of and structure-activity relationships in a series of glycine anilide ACAT inhibitors Bioorganic & Medicinal Chemistry ·W. Howard Roark,Janak Padia,Gary L. Bolton,C. John Blankley,Arnold D. Essenburg,Richard L. Stanfield,Richard F. Bousley,E Zs,Bruce D. Roth	1995	3
5	Inhibitors of Acyl-CoA:Cholesterol O-Acyl Transferase (ACAT) as Hypocholesterolemic Agents. 8. Incorporation of Amide or Amine Functionalities into a Series of Disubstituted Ureas and Carbamates. Effects on ACAT Inhibition in vitro and Efficacy in vivo Journal of Medicinal Chemistry ·Philip O’Brien,Drago R. Sliskovic,C. John Blankley,Bruce D. Roth,D. P. Bow,Louis M. Johnson,Brian R. Krause,Richard L. Stanfield	1994	45
6	Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents Journal of Medicinal Chemistry ·Bharat K. Trivedi,Ann Holmes,S G Oestlund,C. John Blankley,W. Howard Roark,Joseph A. Picard,J. W. NOLAN,Arnold D. Essenburg,Richard L. Stanfield,E Zs	1993	47
7	Inhibitors of acyl-CoA:cholesterol acyltransferase. 5. Identification and structure-activity relationships of novel .beta.-keto amides as hypocholesterolemic agents Journal of Medicinal Chemistry ·Corinne E. Augelli‐Szafran,C. John Blankley,Bruce D. Roth,Bharat K. Trivedi,Richard F. Bousley,Arnold D. Essenburg,Katherine L. Hamelehle,Brian R. Krause,Richard L. Stanfield	1993	22
8	Inhibitors of acyl-CoA:cholesterol acyltransferase. 1. Identification and structure-activity relationships of a novel series of fatty acid anilide hypocholesterolemic agents Journal of Medicinal Chemistry ·Bruce D. Roth,C. John Blankley,M. L. HOEFLE,Ann Holmes,W. Howard Roark,Bharat K. Trivedi,Arnold D. Essenburg,Karen A. Kieft,Brian R. Krause,Richard L. Stanfield	1992	57
9	Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones Journal of Medicinal Chemistry ·Drago R. Sliskovic,C. John Blankley,Brian R. Krause,Roger S. Newton,Daniel Covatariu,W. Howard Roark,Bruce D. Roth,Catherine Sekerke,Maxwell K. Shaw,Richard L. Stanfield	1992	16
10	ANGIOTENSIN II RECEPTOR BINDING INHIBITORS John C. Hodges,James M. Hamby,C. John Blankley	1992	20
11	Inhibitors of cholesterol biosynthesis. 3. Tetrahydro-4-hydroxy-6-[2-(1H-pyrrol-1-yl)ethyl]-2H-pyran 2-one inhibitors of HMG-CoA reductase. 2. Effects of introducing substituents at positions three and four of the pyrrole nucleus Journal of Medicinal Chemistry ·Bruce D. Roth,C. John Blankley,Alexander Chucholowski,Erika Ferguson,M. L. HOEFLE,Daniel F. Ortwine,Roger S. Newton,Catherine Sekerke,Drago R. Sliskovic,Michael Wilson	1991	151
12	N6-Substituted adenosine receptor agonists: potential antihypertensive agents Journal of Medicinal Chemistry ·Bharat K. Trivedi,C. John Blankley,James A. Bristol,Harriet W. Hamilton,William C. Patt,Walter Krämer,IP Kelly,Robert F. Bruns,Daniel M. Cohen,Michael J. Ryan	1991	28
13	Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase Journal of Medicinal Chemistry ·Bruce D. Roth,Thomas Bocan,C. John Blankley,Alexander Chucholowski,Paul L. Creger,Óscar Valdemoros,Erika Ferguson,Roger S. Newton,Patrick O’Brien	1991	46
14	Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype Journal of Medicinal Chemistry ·C. John Blankley,John C. Hodges,S. KLUTCHKO,Richard J. Himmelsbach,Alexander Chucholowski,Cleo J. C. Connolly,W H Snelling,Michael S. Van Nieuwenhze,澄雄柳沼	1991	131
15	ChemInform Abstract: Inhibitors of Cholesterol Biosynthesis. Part 3. Tetrahydro‐4‐hydroxy‐6‐ (2‐(1H‐pyrrol‐1‐yl)ethyl)‐2H‐pyran‐2‐one Inhibitors of HMG‐CoA Reductase. Part 2. Effects of Introducing Substituents at Positions Three and Four of the Pyrrole Nucleus. ChemInform ·Bruce D. Roth,C. John Blankley,Alexander Chucholowski,Erika Ferguson,M. L. HOEFLE,Daniel F. Ortwine,Roger S. Newton,Catherine Sekerke,Drago R. Sliskovic,義六藤井,D. P. Bow	1991	1
16	ChemInform Abstract: 4,5,6,7‐Tetrahydro‐1H‐imidazo(4,5‐c)pyridine‐6‐carboxylic Acids (Spinacines). ChemInform ·S. KLUTCHKO,John C. Hodges,C. John Blankley,Norman L. Colbry	1991	1
17	Synthesis and structure activity relationships of potent new angiotensin converting enzyme inhibitors containing saturated bicyclic amino acids Journal of Medicinal Chemistry ·C. John Blankley,MarcusM. Reidenberg,Anne Tybjærg-Hansen,Andreas Werner,Leslie R. Bennett,А.П. Міщенко,Alfredo E. Altamirano,مهدی عبدالکریمی,Х М Машхур	1987	40
18	Chronicals of Drug Discovery, vol. 2 Journal of Pharmaceutical Sciences ·C. John Blankley	1985	1
19	Biologically active phospholipids as potential cardiovascular drugs Drug Development Research ·C. John Blankley,Harvey Kaplan	1984	4
20	Perhydroindan derivatives. VII. Stereochemistry of bridgehead alkylation The Journal of Organic Chemistry ·Herbert O. House,C. John Blankley	1967	8

About C. John Blankley

C. John Blankley is a scholar working on Toxicology, Physiology and Organic Chemistry, having authored 33 papers that have together received 1.0k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (11 papers), Cholesterol and Lipid Metabolism (6 papers), Computational Drug Discovery Methods (4 papers), Receptor Mechanisms and Signaling (4 papers), Steroid Chemistry and Biochemistry (4 papers), Cancer, Lipids, and Metabolism (3 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). The work is most often cited by research in Organic Chemistry (510 citations), Computational Theory and Mathematics (123 citations) and Molecular Biology (419 citations). C. John Blankley has collaborated with scholars based in United States, United Kingdom and Russia. Frequent co-authors include Herbert O. House, Alexander Chucholowski, Bruce D. Roth, Robert W. Fleming, M. L. HOEFLE, S. KLUTCHKO, John C. Hodges, Drago R. Sliskovic, Richard L. Stanfield and Ronald D. Smith. Their work appears in journals such as Journal of Medicinal Chemistry, The Journal of Organic Chemistry, Journal of Pharmaceutical Sciences, Life Sciences and Bioorganic & Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact